Novo Nordisk and Eli Lilly currently control 99% of the market, but their dominance may weaken as new entrants introduce ...
Novo Nordisk says many Australians would be willing to pay the out-of-pocket costs for its blockbuster medicines, which can ...
Bernstein analysts told investors in a note Tuesday that Eli Lilly (NYSE: LLY) is gaining ground in the GLP-1 market, edging ...
Investing.com - Eli Lilly (NYSE:LLY) announced on Tuesday that it would begin selling 7.5 milligram and 10 milligram single-dose vials of its Zepbound weight-loss drug at a roughly $150 discount to ...
Many employers and insurers are scaling back coverage of Wegovy and Zepbound and a key government program, Medicare, doesn’t cover the drugs for obesity. Meanwhile, some big employers are adding ...
In December, the agency said the same thing when it declared that shortages had ended for Eli Lilly and Co.'s Zepbound and Mounjaro. Zepbound is approved to treat obesity and Mounjaro is approved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results